European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases
复制标题
DOI：
10.1093/ecco-jcc/jju009
复制
发表时间：
2015-03-01
影响因子：
8
通讯作者：
Vavricka, Stephan
中科院分区：
文献类型：
--
作者：
Dignass, Axel U.;Gasche, Christoph;Vavricka, Stephan
贫血是炎症性肠病最常见的全身并发症和肠外表现。1-3在大多数情况下，IBD相关性贫血是慢性缺铁和慢性病贫血[ACD]结合的独特例子。4，5 IBD贫血的其他更罕见的原因包括维生素B12和叶酸缺乏，药物的毒性作用等。贫血对IBD患者生活质量的影响是巨大的。它影响生活质量的各个方面，如身体，情感和认知功能，工作能力，住院和医疗费用。6 IBD中的贫血不仅仅是一种实验室标志物;它是IBD的一种并发症，需要适当的诊断和治疗方法。3.尽管广泛使用抗炎治疗，但贫血在成功治疗后可能很快复发。由于贫血是一种严重的疾病，可能危及生命[如果输血不可用或不相容]，应考虑采取预防措施。欧洲克罗恩病和结肠炎组织[ECCO]发起的这一共识的目标是建立欧洲共识指南，用于诊断、治疗和预防缺铁和缺铁性贫血[IDA]，以及非缺铁性贫血和相关疾病。该共识部分基于先前关于炎症性肠病中缺铁和贫血的诊断和管理的循证共识出版物。7达成共识的战略涉及若干步骤，并遵循欧洲联盟委员会通信组织共识准则的标准作业程序。公开呼吁主席和与会者达成这一共识[见附件和www. ecco-ibd]。参与者
Anaemia is the most common systemic complication and extraintestinal manifestation of inflammatory bowel disease [IBD]. 1–3 In the majority of cases, IBD-associated anaemia is a unique example of the combination of chronic iron deficiency and anaemia of chronic disease [ACD]. 4, 5 Other more rare causes of anaemia in IBD include vitamin B12 and folate deficiency, toxic effects of medications, and others. The impact of anaemia on the quality of life of IBD patients is substantial. It affects various aspects of quality of life such as physical, emotional, and cognitive functions, the ability to work, hospitalization, and healthcare costs. 6 Anaemia in IBD is not just a laboratory marker; it is a complication of IBD that needs appropriate diagnostic and therapeutic approaches. 3 Despite the broad use of anti-inflammatory therapy, anaemia may recur fast after successful therapy. As anaemia is a serious medical condition that may become life threatening [if blood transfusions are not available or compatible], preventive measures should be considered. Prevention of anaemia and maintenance of iron and vitamin stores are therefore warranted.The goal of this consensus initiated by the European Crohn’s and Colitis Organisation [ECCO] was to establish European consensus guidelines for the diagnosis, treatment and prevention of iron deficiency and iron deficiency anaemia [IDA], but also for non-iron deficiency anaemia and associated conditions. The consensus is based in parts on a previous evidence-based consensus publication on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. 7 The strategy to reach the consensus involved several steps and follows the standard operating procedures for consensus guidelines of ECCO. An open call for chairs and participants for this consensus was made [see acknowledgements and www. ecco-ibd]. Participants